additional contraceptive methods are recommended for 4 weeks after initiation and after each dose increase [3] [6] Tirzepatide is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis Patients should inform all healthcare providers, including surgical teams, about tirzepatide use Treatment is likely long-term, as weight regain typically occurs upon discontinuation Patients should be monitored for adequate nutrition and hydration, particularly if appetite suppression is pronounced
For a patient interested in a GLP-1 prescription, the FDA black-box family-history questions, the pregnancy and breastfeeding status check, the eating-disorder screen, the pancreatitis and thyroid-cancer history, and the mental-health review are all asked by the clinician during the visit rather than on a pre-committed online questionnaire
Age: A study published in a 2021 issue of Science debunked the notion that our metabolism slows in adulthood as we age
And the numbers from clinical trials paint a clear picture of how these two medications compare when it comes to the outcome most people care about: how much weight you actually lose
According to a Gallup poll cited by HuffPost, 11% of American adults have taken a GLP-1 medication, up from just 3% in 2024, underscoring how quickly the drugs have become part of mainstream medical care